Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Arrhythmias

Free Subscription Articles published in J Thromb Thrombolysis Retrieve available abstracts of 55 articles: HTML format

Single Articles

March 2023
1. CEREJA F, Alves M, Ferreira JJ, Caldeira D, et al
   Atrial fibrillation risk on Parkinson's disease - a systematic review and meta-analysis.
   J Thromb Thrombolysis. 2023 Mar 25. doi: 10.1007/s11239-023-02792.
   PubMed     Abstract available
   
   
   
2. BERTEOTTI M, Gori AM, Giusti B, Fortini A, et al
   Clinical impact of high platelet reactivity in patients with atrial fibrillation and concomitant percutaneous coronary intervention on dual or triple antithrombotic therapy.
   J Thromb Thrombolysis. 2023 Mar 11. doi: 10.1007/s11239-023-02784.
   PubMed     Abstract available
   
   
   February 2023
3. CLINE L, Generoso EMG, D'Apice N, Dellinger SK, et al
   Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min.
   J Thromb Thrombolysis. 2023;55:355-364.
   PubMed     Abstract available
   
   
   
4. SIEGAL DM, Freedman D, Ansell J
   Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review.
   J Thromb Thrombolysis. 2023;55:197-202.
   PubMed     Abstract available
   
   
   
5. COSTA LSD, Alsultan MM, Hincapie AL, Guo JJ, et al
   Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020.
   J Thromb Thrombolysis. 2023;55:339-345.
   PubMed     Abstract available
   
   
   January 2023
6. DECAMILLO D, Haymart B, Kong X, Kaatz S, et al
   Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation.
   J Thromb Thrombolysis. 2023 Jan 30. doi: 10.1007/s11239-023-02777.
   PubMed     Abstract available
   
   
   
7. JANSSON M, Sjalander S, Sjogren V, Bjorck F, et al
   Reduced dose direct oral anticoagulants compared with warfarin with high time in therapeutic range in nonvalvular atrial fibrillation.
   J Thromb Thrombolysis. 2023 Jan 6. doi: 10.1007/s11239-022-02763.
   PubMed     Abstract available
   
   
   
8. WANG K, Lu Y, Simegn MA, Xue H, et al
   Use of SAMe-TT(2)R(2) in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation.
   J Thromb Thrombolysis. 2023;55:175-180.
   PubMed     Abstract available
   
   
   
9. FELDEISEN D, Alexandris-Souphis C, Haymart B, Gu X, et al
   Higher OAK (Oral Anticoagulation Knowledge) score at baseline associated with better TTR (Time in Therapeutic Range) in patients taking warfarin.
   J Thromb Thrombolysis. 2023;55:141-148.
   PubMed     Abstract available
   
   
   
10. POLZIN A, Helten C, Metzen D, Zako S, et al
    TAVR: nemesis of NOACs?
    J Thromb Thrombolysis. 2023;55:181-184.
    PubMed     Abstract available
    
    
    
11. AMIRTABAR A, Vazquez SR, Saunders J, Witt DM, et al
    Antiplatelet therapy indication in patients also prescribed direct oral anticoagulants.
    J Thromb Thrombolysis. 2023;55:185-188.
    PubMed     Abstract available
    
    
    December 2022
12. WANG M, Yang Y, Luan M, Wang Y, et al
    Role of cerebral microbleeds in acute ischemic stroke and atrial fibrillation.
    J Thromb Thrombolysis. 2022 Dec 26. doi: 10.1007/s11239-022-02761.
    PubMed     Abstract available
    
    
    
13. HANTRAKUN N, Wongcharoen W, Thiankhaw K, Norasetthada L, et al
    Impact of dabigatran dose on drug levels in asian patients with atrial fibrillation or venous thromboembolism: evidence from pharmacological to clinical outcomes.
    J Thromb Thrombolysis. 2022 Dec 9. doi: 10.1007/s11239-022-02747.
    PubMed     Abstract available
    
    
    
14. CARBONE A, Bottino R, Attena E, Parisi V, et al
    Clinical impact of oral anticoagulation among octogenarians with atrial fibrillation and anaemia.
    J Thromb Thrombolysis. 2022 Dec 6. doi: 10.1007/s11239-022-02740.
    PubMed     Abstract available
    
    
    November 2022
15. LIANOS I, Varlamos C, Benetou DR, Mantis C, et al
    Platelet function testing in atrial fibrillation patients undergoing percutaneous coronary intervention.
    J Thromb Thrombolysis. 2022 Nov 12. pii: 10.1007/s11239-022-02723.
    PubMed     Abstract available
    
    
    October 2022
16. YE TTS, Siah QZ, Tan BYQ, Ho JSY, et al
    Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2022 Oct 3. pii: 10.1007/s11239-022-02713.
    PubMed     Abstract available
    
    
    September 2022
17. SERRAO A, Malfona F, Assanto GM, Orellana MGC, et al
    Direct oral anticoagulants for the treatment of atrial fibrillation in patients with hematologic malignancies.
    J Thromb Thrombolysis. 2022 Sep 20. pii: 10.1007/s11239-022-02702.
    PubMed     Abstract available
    
    
    June 2022
18. NOVAK AR, Shakowski C, Trujillo TC, Wright GC, et al
    Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism.
    J Thromb Thrombolysis. 2022 Jun 10. pii: 10.1007/s11239-022-02668.
    PubMed     Abstract available
    
    
    May 2022
19. LIP GYH, Keshishian A, Kang A, Luo X, et al
    Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases.
    J Thromb Thrombolysis. 2022 May 17. pii: 10.1007/s11239-022-02660.
    PubMed     Abstract available
    
    
    April 2022
20. MARTINEZ KA, Eckman MH, Pappas MA, Rothberg MB, et al
    Prescribing of anticoagulation for atrial fibrillation in primary care.
    J Thromb Thrombolysis. 2022 Apr 21. pii: 10.1007/s11239-022-02655.
    PubMed     Abstract available
    
    
    
21. DING WY, Rivera-Caravaca JM, Marin F, Roldan V, et al
    Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.
    J Thromb Thrombolysis. 2022 Apr 15. pii: 10.1007/s11239-022-02638.
    PubMed     Abstract available
    
    
    
22. FROL S, Hudnik LK, Sernec LP, Sabovic M, et al
    Direct oral anticoagulants for secondary stroke prevention in patients over 80 years of age: the role of geriatric functional status.
    J Thromb Thrombolysis. 2022;53:607-615.
    PubMed     Abstract available
    
    
    
23. DECAMILLO D, Haymart B, Barnes GD
    Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    J Thromb Thrombolysis. 2022;53:601-606.
    PubMed     Abstract available
    
    
    February 2022
24. POTERE N, Candeloro M, Porreca E, Marinari S, et al
    Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone.
    J Thromb Thrombolysis. 2022;53:346-351.
    PubMed     Abstract available
    
    
    
25. MEADOR S, Dyke S, Togami J, Kuskov B, et al
    Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics.
    J Thromb Thrombolysis. 2022;53:436-445.
    PubMed     Abstract available
    
    
    
26. GALLI M, Gargiulo G
    Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment.
    J Thromb Thrombolysis. 2022;53:495-498.
    PubMed    
    
    
    January 2022
27. BAI Y, Liu XY, Liu Y, Guo SD, et al
    Prevalence of recommended anticoagulation by guidelines preadmission and its impact on the incidence of acute myocardial infarction (AMI) and in-hospital outcomes after AMI in atrial fibrillation patients.
    J Thromb Thrombolysis. 2022 Jan 24. pii: 10.1007/s11239-021-02622.
    PubMed     Abstract available
    
    
    October 2021
28. LV WH, Dong JZ, Du X, Hu R, et al
    Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome.
    J Thromb Thrombolysis. 2021 Oct 22. pii: 10.1007/s11239-021-02588.
    PubMed     Abstract available
    
    
    
29. BEWERSDORF JP, Parmar N, Israel GM, Gettinger SN, et al
    Clinical characteristics and outcomes of splenic infarction in cancer patients: a retrospective, single center report of 206 cases.
    J Thromb Thrombolysis. 2021;52:854-862.
    PubMed     Abstract available
    
    
    
30. CHEN Y, Zhang Y, Qu L, Huang W, et al
    Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure.
    J Thromb Thrombolysis. 2021;52:872-879.
    PubMed     Abstract available
    
    
    
31. NISLY SA, Mihm AE, Gillette C, Davis KA, et al
    Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:817-827.
    PubMed     Abstract available
    
    
    
32. SADIQ H, Hoque L, Shi Q, Manning G, et al
    SUPPORT-AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF.
    J Thromb Thrombolysis. 2021;52:808-816.
    PubMed     Abstract available
    
    
    September 2021
33. PAPANASTASIOU A, Kartas A, Samaras A, Vrana E, et al
    Oral anticoagulation patterns and prognosis in octogenarian patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 25. pii: 10.1007/s11239-021-02571.
    PubMed     Abstract available
    
    
    
34. WANG CL, Wu VC, Tu HT, Huang YT, et al
    Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation.
    J Thromb Thrombolysis. 2021 Sep 23. pii: 10.1007/s11239-021-02570.
    PubMed     Abstract available
    
    
    
35. OBI CA, Bulsara K, Izard S, Delicce A, et al
    Examination of anticoagulation prescription among elderly patients with atrial fibrillation after in-hospital fall.
    J Thromb Thrombolysis. 2021 Sep 4. pii: 10.1007/s11239-021-02555.
    PubMed     Abstract available
    
    
    
36. CHEN J, Zhou M, Wang H, Zheng Z, et al
    Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score.
    J Thromb Thrombolysis. 2021 Sep 2. pii: 10.1007/s11239-021-02554.
    PubMed     Abstract available
    
    
    August 2021
37. MENDOZA PA, McIntyre WF, Belley-Cote EP, Wang J, et al
    Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis.
    J Thromb Thrombolysis. 2021 Aug 2. pii: 10.1007/s11239-021-02530.
    PubMed     Abstract available
    
    
    
38. AFZAL S, Zaidi STR, Merchant HA, Babar ZU, et al
    Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting.
    J Thromb Thrombolysis. 2021;52:646-653.
    PubMed     Abstract available
    
    
    
39. ROMOLI M, Marchetti G, Bernardini F, Urbinati S, et al
    Switching between direct oral anticoagulants: a systematic review and meta-analysis.
    J Thromb Thrombolysis. 2021;52:560-566.
    PubMed     Abstract available
    
    
    
40. BASS ME, Kiser TH, Page RL 2nd, McIlvennan CK, et al
    Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus.
    J Thromb Thrombolysis. 2021;52:517-522.
    PubMed     Abstract available
    
    
    July 2021
41. LI RJ, Caughey GE, Shakib S
    Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jul 24. pii: 10.1007/s11239-021-02528.
    PubMed     Abstract available
    
    
    
42. KAO CC, Wang T, Parulekar AD
    Need for anticoagulation and use of direct oral anticoagulants in lung transplant recipients.
    J Thromb Thrombolysis. 2021;52:232-238.
    PubMed     Abstract available
    
    
    
43. ROSSIER C, Spoutz P, Schaefer M, Allen A, et al
    Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management.
    J Thromb Thrombolysis. 2021;52:200-208.
    PubMed     Abstract available
    
    
    
44. WALLVIK N, Renlund H, Sjalander A
    Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants.
    J Thromb Thrombolysis. 2021;52:315-323.
    PubMed     Abstract available
    
    
    
45. SYLVESTER KW, Wagner C, Lewin A, Fanikos J, et al
    Reasons for new patient warfarin referrals to an anticoagulant management service in 2019: a single institution experience.
    J Thromb Thrombolysis. 2021;52:158-160.
    PubMed    
    
    
    June 2021
46. LU X, Chen T, Liu G, Guo Y, et al
    Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation.
    J Thromb Thrombolysis. 2021 Jun 15. pii: 10.1007/s11239-021-02490.
    PubMed     Abstract available
    
    
    May 2021
47. PIAZZA G, Hurwitz S, Goldhaber SZ
    Stroke risk factors and outcomes among hospitalized women with atrial fibrillation.
    J Thromb Thrombolysis. 2021 May 26. pii: 10.1007/s11239-021-02482.
    PubMed     Abstract available
    
    
    
48. BERNAITIS N, Badrick T, Anoopkumar-Dukie S
    Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy.
    J Thromb Thrombolysis. 2021 May 7. pii: 10.1007/s11239-021-02466.
    PubMed     Abstract available
    
    
    
49. GUNER A, Kalcik M, Gunduz S, Gursoy MO, et al
    The relationship between incomplete surgical obliteration of the left atrial appendage and thromboembolic events after mitral valve surgery (from the ISOLATE Registry).
    J Thromb Thrombolysis. 2021;51:1078-1089.
    PubMed     Abstract available
    
    
    
50. MARCATTO L, Boer B, Sacilotto L, Olivetti N, et al
    Impact of adherence to warfarin therapy during 12 weeks of pharmaceutical care in patients with poor time in the therapeutic range.
    J Thromb Thrombolysis. 2021;51:1043-1049.
    PubMed     Abstract available
    
    
    April 2021
51. VINEREANU D, Napalkov D, Bergler-Klein J, Benczur B, et al
    Patient perceptions of anticoagulant treatment with dabigatran or a vitamin K antagonist for stroke prevention in atrial fibrillation according to region and age: an exploratory analysis from the RE-SONANCE study.
    J Thromb Thrombolysis. 2021 Apr 30. pii: 10.1007/s11239-021-02450.
    PubMed     Abstract available
    
    
    
52. BARTOLAZZI F, Ribeiro ALP, de Sousa WJFN, Vianna MS, et al
    Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross-sectional study.
    J Thromb Thrombolysis. 2021 Apr 15. pii: 10.1007/s11239-021-02432.
    PubMed     Abstract available
    
    
    February 2021
53. GAVIN O, Grandes J, Garcia MA, Marzo C, et al
    Treatment preferences as basis for decision making in patients using direct oral anticoagulants in Spain.
    J Thromb Thrombolysis. 2021;51:475-484.
    PubMed     Abstract available
    
    
    January 2021
54. NABAVIZADEH P, Steen DL
    Highlights from the European society of cardiology congress 2020.
    J Thromb Thrombolysis. 2021;51:232-236.
    PubMed    
    
    
    July 2020
55. DIEP R, Garcia D
    Should we monitor the direct oral anticoagulants?
    J Thromb Thrombolysis. 2020;50:30-32.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Arrhythmias is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: